Becton, Dickinson and Company $BDX Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 23.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 103,737 shares of the medical instruments supplier’s stock after selling 31,013 shares during the quarter. Corient Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $17,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Saudi Central Bank purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $26,000. Bell Investment Advisors Inc grew its holdings in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the period. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter worth approximately $31,000. Bank of Jackson Hole Trust raised its stake in Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares during the period. Finally, WPG Advisers LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $36,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $195.46 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The company has a market capitalization of $55.79 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.81 and a beta of 0.25. The business has a 50-day moving average of $189.18 and a 200-day moving average of $185.09.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. The trade was a 4.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,036 shares of company stock valued at $197,225. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on BDX shares. Piper Sandler dropped their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Jefferies Financial Group raised their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Finally, Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $205.64.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.